Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Military Members, Families And Retirees Get Simplified Access To Abbott's Freestyle® Libre 2 System Through Tricare®

CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review - Pemberton - 2023 - Diabetes, Obesity and Metabolism - Wiley Online Library

FreeStyle Libre 2 System

Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project

Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

FreeStyle Libre 2 System (CGM)

FreeStyle Libre 2 System (CGM)

Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®

FreeStyle Libre Continuous Glucose Monitoring

Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in well‐controlled youth with type 1 diabetes - Charleer - 2020 - Pediatric Diabetes - Wiley Online Library

Freestyle Libre 2 CGM, Strategy and Strength

FreeStyle Libre 2 Continuous Glucose Monitor